VIVUS Qnexa data “will be presented at the European Congress focused on prevention and cardiac rehabilitation

EuroPRevent 2010, the Annual Congress of the European Association for Cardiovascular Prevention and Rehabilitation, Hilton Prague, Prague, Czech RepublicVIVUS is a biopharmaceutical company developing innovative, next-generation therapies to meet unmet needs in obesity, sleep apnea and sexual health. The company’s flagship product in clinical development, Qnexa, has completed Phase 3 clinical trials for the treatment of obesity and an NDA has been submitted and accepted by the FDA, with a given action of October 28, 2010. Qnexa is in Phase 2 clinical development for the treatment of type 2 diabetes. In the field of sexual health, VIVUS is in phase 3 development with avanafil, a potential best-in-class PDE5 inhibitors for the treatment. MUSE , a first generation therapy for the treatment of erectile dysfunction, is already on the market and generate income for VIVUS

‘We are pleased to share the Qnexa lipids and clinical data with our medical colleagues and industry in Europe in this prestigious conference,’ said Peter Tam, President, VIVUS. ‘Earlier this week, Dr. Oparil shared pool of 28 weeks antihypertensive Qnexa data with colleagues in cardiology by the American Society of Hypertension. We are pleased to be part of this and other important clinical encounters. ‘

The new criteria to add more credibility to fibromyalgia, such as all types of physicians, not only rheumatologists, should be easier to diagnose, Katz.

Session: Poster Session 3: Health Policy and Prevention: Services of obesity, nutrition and health

Title of presentation: 12 months rate of weight loss with PHEN and triglycerides / TPM CR patients are overweight or obese with hypertriglyceridemia.

VIVUS Qnexa data “will be presented at the European Congress focused on prevention and cardiac rehabilitation